SCHEMBL4155339

SCHEMBL4155339

CS(=O)(=O)c1cccc(-c2ccc3[nH]c(=O)c4[nH]cc(CCC(=O)O)c4c3c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 2/20 0.40
FASN P49327 1/20 0.38
PDPK1 O15530 1/20 0.37
EGFR P00533 2/20 0.37
PDGFRB P09619 2/20 0.37
FGFR1 P11362 2/20 0.37
KDR P35968 2/20 0.37
IKBKB O14920 2/20 0.37
GPR17 Q13304 2/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
ICMT O60725 1/20 0.35
GRK6 P43250 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4153846 0.94 CAMKK2 (0.39) CAMKK2FASNPDPK1IKBKBGRIN2D
SCHEMBL4155187 0.91 HPGD (0.38) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL4153837 0.87 GPR17 (0.45) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL4159323 0.87 FASN (0.45) CAMKK2FASNGPR17GRK6F7
SCHEMBL4161892 0.86 TDP2 (0.39) CAMKK2HPGDCYP2C19SPRMEN1
SCHEMBL4157978 0.85 HPGD (0.39) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL4166164 0.85 GPR17 (0.40) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL4157563 0.84 HPGD (0.49) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL4163088 0.83 GRIN2D (0.45) EGFRPDGFRBFGFR1KDRIKBKB
SCHEMBL3242761 0.83 CAMKK2 (0.46) CAMKK2FASNPDPK1PARP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 CAMKK2 43/4885FASN 2527/4885PDPK1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.